反相色谱 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Li R, Bianchet MA, Talalay P, Amzel LM (1995). "The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction". Proc. Natl. Acad. Sci. U.S.A. 92 (19): 8846–50. Bibcode:1995PNAS...92.8846L. doi:10.1073/pnas.92.19.8846. PMC 41064. PMID 7568029.
== Regulation == Protein concentration, which in turn are affected by expression levels and degradation rates; Protein affinity for proteins or other binding ligands; Ligands concentrations (substrates, ions, etc.); Presence of other proteins, nucleic acids, and ions; Electric fields around proteins. Occurrence of covalent modifications;
=== Gold nanoparticle based biosensor === Gold nanoparticles are incorporated into biosensors to enhance its stability, sensitivity, and selectivity. Nanoparticle properties such as small size, high surface-to-volume ratio, and high surface energy allow immobilization of large range of biomolecules. Gold nanoparticle, in particular, could also act as "electron wire" to transport electrons and its amplification effect on electromagnetic light allows it to function as signal amplifiers. Main types of gold nanoparticle based biosensors are optical and electrochemical biosensor.
EC 1.1.99.9: pyridoxine 5-dehydrogenase EC 1.1.99.10: Now EC 1.1.5.9, glucose 1-dehydrogenase (FAD, quinone) EC 1.1.99.11: Now classified as EC 1.1.5.14, fructose 5-dehydrogenase EC 1.1.99.12: sorbose dehydrogenase EC 1.1.99.13: glucoside 3-dehydrogenase EC 1.1.99.14: glycolate dehydrogenase EC 1.1.99.15: Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.99.16: Now EC EC 1.1.5.4, malate dehydrogenase (quinone) EC 1.1.99.17: Now EC 1.1.5.2, quinoprotein glucose dehydrogenase EC 1.1.99.18: cellobiose dehydrogenase (acceptor) EC 1.1.99.19: Now EC 1.17.99.4, uracil/thymine dehydrogenase EC 1.1.99.20: alkan-1-ol dehydrogenase (acceptor) EC 1.1.99.21: D-sorbitol dehydrogenase (acceptor) EC 1.1.99.22: glycerol dehydrogenase (acceptor) EC 1.1.99.23: Now EC 1.1.2.6, polyvinyl alcohol dehydrogenase (cytochrome) EC 1.1.99.24: hydroxyacid-oxoacid transhydrogenase EC 1.1.99.25: Now EC 1.1.5.8, quinate dehydrogenase (quinone), EC 1.1.99.26: 3-hydroxycyclohexanone dehydrogenase EC 1.1.99.27: (R)-pantolactone dehydrogenase (flavin) EC 1.1.99.28: glucose-fructose oxidoreductase EC 1.1.99.29: pyranose dehydrogenase (acceptor) EC 1.1.99.30: 2-oxoacid reductase EC 1.1.99.31: (S)-mandelate dehydrogenase EC 1.1.99.32: L-sorbose 1-dehydrogenase EC 1.1.99.33: Now EC 1.17.99.7, formate dehydrogenase (acceptor) EC 1.1.99.34: now EC 1.1.98.2, glucose-6-phosphate dehydrogenase (coenzyme-F420) EC 1.1.99.35: soluble quinoprotein glucose dehydrogenase EC 1.1.99.36: alcohol dehydrogenase (nicotinoprotein) EC 1.1.99.37: methanol dehydrogenase (nicotinoprotein) EC 1.1.99.38: 2-deoxy-scyllo-inosamine dehydrogenase (AdoMet-dependent) EC 1.1.99.39: D-2-hydroxyglutarate dehydrogenase EC 1.1.99.40: (R)-2-hydroxyglutarate—pyruvate transhydrogenase EC 1.1.99.41: 3-hydroxy-1,2-didehydro-2,3-dihydrotabersonine reductase EC 1.1.99.42: 4-pyridoxic acid dehydrogenase
It appears in the sex cord-stromal tumour group of ovarian neoplasms. Ovary fibromas are most frequent during middle age, and rare in children. Upon gross pathological inspection, ovary fibromas are firm and white or tan. Variants with edema are especially likely to be associated with Meigs' syndrome. On microscopic examination, there are intersecting bundles of spindle cells producing collagen. There may be thecomatous areas (fibrothecoma). The presence of an ovarian fibroma can cause ovarian torsion in some cases.
Sources: en.wikipedia.org
== Food and Drug Administration == The FDA has minimal control when regulating dietary supplements like pre-workout. Product manufacturers are responsible to verify that dietary supplements are safe for consumption. Financial limitations prevent the FDA from testing dietary supplements before they enter the marketplace. Once a supplement is available for sale, the FDA is responsible to document and monitor manufacturer reports of adverse effects. Manufacturers are obligated to report documented adverse effects to the FDA. The FDA recommends speaking with a healthcare professional before using dietary supplements. Ingredients in pre-workout can have negative side effects or contraindications with other medications. Taking dietary supplements may have life-threatening consequences if taken with pre-existing health conditions. Federal laws state that a supplement does not have to be declared safe by FDA standards when labeled. Most supplement businesses hire third-party companies to identify the contents of their supplement to ensure it enhances athletic performance. This also aids in assuring that a product's labeled ingredients are free from illegal substances.
=== 2015 === The index crossed the historical mark of 30,000 after repo rate cut announcement by RBI. The index plummeted by over 1,624.51 points on 24 August 2015, the then worst one-day point plunge in the index's history.
Ammonium NH+4 Calcium Ca2+ Iron Fe2+ and Fe3+ Magnesium Mg2+ Potassium K+ Pyridinium C5H5NH+ Quaternary ammonium NR+4, R being an alkyl group or an aryl group Sodium Na+ Copper Cu2+ Common salt-forming anions (parent acids in parentheses where available) include:
== Structure and toxicity == Amyloid beta is commonly thought to be intrinsically unstructured, meaning that in solution it does not acquire a unique tertiary fold but rather populates a set of structures. As such, it cannot be crystallized and most structural knowledge on amyloid beta comes from NMR and molecular dynamics. Early NMR-derived models of a 26-aminoacid polypeptide from amyloid beta (Aβ 10–35) show a collapsed coil structure devoid of significant secondary structure content. However, the most recent (2012) NMR structure of (Aβ 1-40) has significant secondary and tertiary structure. Replica exchange molecular dynamics studies suggested that amyloid beta can indeed populate multiple discrete structural states; more recent studies identified a multiplicity of discrete conformational clusters by statistical analysis. By NMR-guided simulations, amyloid beta 1-40 and amyloid beta 1-42 also seem to feature highly different conformational states, with the C-terminus of amyloid beta 1-42 being more structured than that of the 1-40 fragment. Low-temperature and low-salt conditions can enable formation of pentameric disc-shaped oligomers devoid of beta structure. In contrast, soluble oligomers prepared in the presence of detergents seem to feature substantial beta sheet content with mixed parallel and antiparallel character, different from fibrils; computational studies suggest an antiparallel beta-turn-beta motif instead for membrane-embedded oligomers.
Sources: en.wikipedia.org
Obesity can lead to social stigmatization and disadvantages in employment. When compared to their ideal-weight counterparts, workers with obesity, on average, have higher rates of absenteeism from work and take more disability leave, thus increasing costs for employers and decreasing productivity. A study examining Duke University employees found that people with a BMI over 40 kg/m2 filed twice as many workers' compensation claims as those with a BMI of 18.5 to 24.9 kg/m2. They also had more than 12 times as many lost work-days. The most common injuries in this group were due to falls and lifting, thus affecting the lower extremities, wrists or hands, and backs. The Alabama State Employees' Insurance Board approved a controversial plan to charge obese workers and those with other health conditions $50 a month for health insurance that would otherwise be $25 unless they take steps to lose weight and improve their health. These measures started in January 2010 and apply to those state workers whose BMI exceeds 35 kg/m2 or who have other health conditions and who fail to take steps to make improvements in their health after one year. This becomes a Catch-22 situation, as many insurance companies refuse to pay for treatment methods for workers living with obesity. Some research shows that people with obesity are less likely to be hired for a job and are less likely to be promoted. People with obesity are also paid less than their counterparts (who do not live with obesity) for an equivalent job; women with obesity on average make 6% less and men with obesity make 3% less.
=== Post-1918 Consorts of the Heads of the House === Hermine Reuss of Greiz (1887–1947), second wife of Wilhelm II (married 1922) Duchess Cecilie of Mecklenburg-Schwerin (1886–1954), wife of Crown Prince Wilhelm Grand Duchess Kira Kirillovna of Russia (1909–1967), wife of Prince Louis Ferdinand Princess Sophie of Isenburg (born 1978), wife of Prince Georg Friedrich
In a somewhat ironic twist, after the discovery of ozone, a popular Victorian belief started to attribute health benefits to sea air due to its smell, which was thought to be caused by a high ozone content. That smell is in fact caused by dimethyl sulfide, a sulfur compound.
Approximately one month after the attacks, the United States led a broad coalition of international forces to overthrow the Taliban regime from Afghanistan for their harboring of al-Qaeda. Though Pakistani authorities were initially reluctant to align themselves with the U.S. against the Taliban, they permitted the coalition access to their military bases, and arrested and handed over to the U.S. more than 600 suspected al-Qaeda members. In 2011, the U.S. and NATO under President Obama initiated a drawdown of troops in Afghanistan finalized in 2016. During the presidencies of Donald Trump and Joe Biden in 2020 and 2021, the United States alongside its NATO allies withdrew all troops from Afghanistan, completing the withdrawal of all regular U.S. troops on August 30, 2021. The withdrawal marked the end of the 2001–2021 war in Afghanistan. Biden said that after nearly 20 years of war, it was clear that the U.S. military could not transform Afghanistan into a modern democracy.
Enantiomeric impurities also impede RNA replication and chain elongation, processes central to both modern cellular processes like transcription and the RNA world hypothesis. As homochirality is ubiquitous in extant biology, a key question in origins of life and prebiotic chemistry research is how biological homochirality could have arisen from racemic mixtures of the simple chemical building blocks of life. Many mechanisms for the origin of homochirality have been proposed. Some of these models propose three distinct steps: a mirror-symmetry breaking mechanism to create a minute enantiomeric imbalance (enantiomeric excess or ee) from a racemic mixture, subsequent chiral amplification to achieve a larger ee or full homochirality (i.e., ee=100%), and finally chiral transmission/propagation to transfer chirality from one set of molecules to another. In addition, another important consideration is the environmental plausibility of proposed mechanisms — whether a symmetry breaking, amplification, or propagation process could occur over relevant timescales and using only materials that could feasibly be available prebiotically under early Earth conditions.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。